Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Stock Position Raised by Segantii Capital Management Ltd

Segantii Capital Management Ltd lifted its holdings in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 71.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 32,950 shares of the biopharmaceutical company’s stock after buying an additional 13,700 shares during the period. Segantii Capital Management Ltd’s holdings in Alnylam Pharmaceuticals were worth $6,307,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Charles Schwab Investment Management Inc. raised its holdings in shares of Alnylam Pharmaceuticals by 4.6% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 438,304 shares of the biopharmaceutical company’s stock worth $83,896,000 after acquiring an additional 19,324 shares in the last quarter. Metis Global Partners LLC increased its stake in shares of Alnylam Pharmaceuticals by 2.2% in the fourth quarter. Metis Global Partners LLC now owns 4,382 shares of the biopharmaceutical company’s stock worth $839,000 after purchasing an additional 94 shares during the period. Benjamin F. Edwards & Company Inc. acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $71,000. Los Angeles Capital Management LLC acquired a new stake in Alnylam Pharmaceuticals during the fourth quarter worth about $3,259,000. Finally, First Trust Direct Indexing L.P. grew its position in Alnylam Pharmaceuticals by 13.3% during the fourth quarter. First Trust Direct Indexing L.P. now owns 2,898 shares of the biopharmaceutical company’s stock worth $555,000 after buying an additional 340 shares in the last quarter. Institutional investors and hedge funds own 92.97% of the company’s stock.

Analysts Set New Price Targets

ALNY has been the topic of a number of recent research reports. Wolfe Research initiated coverage on Alnylam Pharmaceuticals in a research report on Thursday, February 15th. They set a “peer perform” rating on the stock. The Goldman Sachs Group lowered shares of Alnylam Pharmaceuticals from a “buy” rating to a “neutral” rating and lowered their price target for the company from $230.00 to $173.00 in a report on Friday, February 16th. Needham & Company LLC reiterated a “buy” rating and set a $200.00 price target on shares of Alnylam Pharmaceuticals in a research report on Thursday, May 2nd. Citigroup reduced their price objective on shares of Alnylam Pharmaceuticals from $237.00 to $227.00 and set a “buy” rating on the stock in a research note on Friday, February 16th. Finally, Wells Fargo & Company reduced their target price on Alnylam Pharmaceuticals from $171.00 to $161.00 and set an “equal weight” rating on the stock in a report on Friday, February 16th. Seven analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $216.19.

Alnylam Pharmaceuticals Stock Performance

NASDAQ:ALNY traded down $0.92 during mid-day trading on Thursday, hitting $151.37. 329,125 shares of the stock were exchanged, compared to its average volume of 745,383. The stock has a market capitalization of $19.15 billion, a price-to-earnings ratio of -56.82 and a beta of 0.41. The firm’s 50-day simple moving average is $149.35 and its 200 day simple moving average is $164.93. Alnylam Pharmaceuticals, Inc. has a fifty-two week low of $141.98 and a fifty-two week high of $218.88.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, May 2nd. The biopharmaceutical company reported ($0.52) earnings per share for the quarter, topping the consensus estimate of ($0.75) by $0.23. The firm had revenue of $494.33 million for the quarter, compared to analyst estimates of $428.01 million. The business’s revenue for the quarter was up 54.8% on a year-over-year basis. During the same period in the previous year, the business posted ($1.40) earnings per share. On average, analysts predict that Alnylam Pharmaceuticals, Inc. will post -4.43 EPS for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.